Advertisement
CR vs EMR
Which Stock Would AI Choose? Crane Company (CR) vs. Emerson Electric (EMR) Stock Comparison
Key Takeaways
- Crane Company (CR) is a smaller, faster-growing engineered-components maker whose momentum is being amplified by recent acquisitions in aerospace, sensing, and process-flow technologies.
- Emerson Electric (EMR) is a large-cap automation leader generating steadier, software-driven growth with strong cash returns to shareholders.
- Crane recently raised guidance and posted double-digit earnings growth, while Emerson delivered consistent single-digit sales growth and margin expansion.
- Emerson offers greater scale, liquidity, and diversification; Crane offers a sharper growth-and-transformation narrative with higher execution risk.
- Relative positioning depends on whether an investor prioritizes growth acceleration and re-rating potential or stability and cash generation.
Introduction
Investors comparing CR and EMR are effectively weighing two different profiles within the industrial and automation landscape. Crane Company (CR) is a mid-cap manufacturer of engineered components for aerospace, defense, and process-flow markets, while Emerson Electric (EMR) is a global automation technology and software giant. Both companies are riding durable demand from aerospace, energy, and electrification, yet they differ sharply in scale, growth trajectory, and risk. This stock comparison is relevant for traders seeking relative-performance signals and for long-term investors evaluating market positioning between a transformation story and an established compounding franchise.
CR Overview and Recent Performance
CR, Crane Company, designs and manufactures highly engineered components for mission-critical applications across aerospace, defense, space, and process-flow industries. The company operates primarily through two segments: Aerospace & Advanced Technologies and Process Flow Technologies. Recent market activity has been defined by an aggressive portfolio repositioning, including the completed acquisitions of Druck, Panametrics, Reuter-Stokes, and optek-Danulat, as well as a pending deal for Precision Sensors & Instrumentation from Baker Hughes.
In its most recent quarterly results, Crane reported sales up roughly 7% year over year alongside adjusted earnings per share (EPS) growth exceeding 20%, driven by aerospace and defense demand and disciplined margin execution. Management initiated forward guidance implying sales growth in the low-to-mid 20% range, reflecting acquisition contributions and mid-single-digit organic growth. The company also announced a leadership transition and an 11% dividend increase. This acquisition-driven growth has supported positive sentiment, though integration costs and temporary margin dilution have tempered near-term expectations.
EMR Overview and Recent Performance
EMR, Emerson Electric, is a multinational automation technology and engineering company serving industrial, commercial, and residential markets. Its two reporting segments are Intelligent Devices and Software & Control, the latter reflecting a strategic pivot toward higher-margin software and automation solutions. Recent quarters have been marked by the completion of the AspenTech and Test & Measurement integrations, including the achievement of roughly $200 million in run-rate cost synergies.
Emerson's most recent fiscal year produced net sales growth of about 5% and adjusted EPS growth near 9%, supported by underlying order growth in North America, India, and the Middle East. Management cited secular tailwinds in electrification, energy security, and near-shoring, alongside demand from power generation, LNG (liquefied natural gas), and data-center projects. The company guided to mid-single-digit sales growth and planned to return roughly $2.2 billion to shareholders through dividends and buybacks. Performance has been steady and reliable, if less dramatic than Crane's acquisition-led acceleration.
Trending AI Robots
For traders who prefer a data-driven, systematic approach, Tickeron's Trending AI Robots page offers a curated view of the platform's AI trading bots. Tickeron hosts hundreds of AI-powered trading bots that collectively trade thousands of different tickers, but only a select group earns a place in the Trending section — those best suited to current market conditions. Each bot operates with its own trading style, strategy, timeframe, performance track record, and statistical profile, and many report win rates and trade volumes that vary widely depending on the tickers they target. Because the featured bots are continuously updated to reflect shifting momentum and volatility, investors can use the section as a starting point for identifying strategies aligned with today's environment. Explore the Trending AI Robots to see which automated approaches are currently gaining traction.
Head-to-Head Comparison
The most visible contrast between CR and EMR is scale and strategy. Emerson is a roughly $80-billion-plus market-cap leader in automation and software, generating tens of billions in annual revenue with diversified geographic and end-market exposure. Crane is a roughly $10-billion company whose growth is being accelerated by a rapid string of acquisitions aimed at expanding its technology and aerospace footprint.
On growth, Crane's recent top-line and earnings momentum has outpaced Emerson's, largely because acquisitions inflate reported growth, whereas Emerson's mid-single-digit expansion is predominantly organic. On margins, both businesses are improving, but Emerson's software mix and scale deliver a structurally higher and steadier profitability profile. Risk profiles also differ: Crane carries integration and leverage risk tied to its acquisition spree and a CEO transition, while Emerson faces cyclical softness in chemical and automotive end markets, particularly in Europe and China. From a market-sentiment standpoint, Crane's transformation narrative has supported multiple expansion and stronger relative momentum, while Emerson's steadier cash returns and buybacks appeal to income- and stability-focused investors. Ultimately, the trade-off is growth acceleration versus durability.
Tickeron AI Verdict
Based on observable trend consistency, relative momentum, and catalyst density, Tickeron's AI would likely lean toward CR in the current environment. Crane has exhibited stronger near-term earnings acceleration, a clearer re-rating catalyst in its acquisition program, and more pronounced positive price momentum relative to the broader industrial sector. At the same time, Emerson's steadier trend, superior cash generation, and lower execution risk would likely keep EMR favored for strategies prioritizing stability and lower volatility. The verdict is therefore probabilistic: a momentum- and catalyst-oriented signal would likely favor Crane, while a stability- and cash-flow-oriented signal would favor Emerson. Neither conclusion constitutes a definitive prediction of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CR is a Hold and EMR is a Buy.
CR sees its Stochastic Oscillator climbs out of oversold territory
On October 13, 2026, the Stochastic Oscillator for CR moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 51 instances where the indicator left the oversold zone. In 41 of the 51 cases the stock moved higher in the following days. This puts the odds of a move higher at over 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +0.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where CR advanced for three days, in 228 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 194 of 276 cases where CR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CR as a result. In 59 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for CR turned negative on October 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 32 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.
CR moved below its 50-day moving average on October 20, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. CR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.342) is normal, around the industry mean (4.503). P/E Ratio (34.523) is within average values for comparable stocks, (38.302). Projected Growth (PEG Ratio) (2.345) is also within normal values, averaging (1.879). Dividend Yield (0.005) settles around the average of (0.029) among similar stocks. P/S Ratio (4.468) is also within normal values, averaging (186.943).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
EMR in upward trend: price rose above 50-day moving average on September 21, 2026
EMR moved above its 50-day moving average on September 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for EMR crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.
Following a +1.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 213 of 342 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 156 of 274 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 60 cases where EMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EMR as a result. In 58 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
The Moving Average Convergence Divergence Histogram (MACD) for EMR turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 27 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 22 (best 1 - 100 worst), indicating outstanding price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 22 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.392) is normal, around the industry mean (4.503). P/E Ratio (34.959) is within average values for comparable stocks, (38.302). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.014) settles around the average of (0.029) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (186.943).
CR | EMR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 43 | 85 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 10 | 22 | |
SMR RATING 1..100 | 52 | 62 | |
PRICE GROWTH RATING 1..100 | 45 | 22 | |
P/E GROWTH RATING 1..100 | 41 | 33 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EMR's Valuation (80) in the Electrical Products industry is in the same range as CR (83) in the null industry. This means that EMR’s stock grew similarly to CR’s over the last 12 months.
CR's Profit vs Risk Rating (10) in the null industry is in the same range as EMR (22) in the Electrical Products industry. This means that CR’s stock grew similarly to EMR’s over the last 12 months.
CR's SMR Rating (52) in the null industry is in the same range as EMR (62) in the Electrical Products industry. This means that CR’s stock grew similarly to EMR’s over the last 12 months.
EMR's Price Growth Rating (22) in the Electrical Products industry is in the same range as CR (45) in the null industry. This means that EMR’s stock grew similarly to CR’s over the last 12 months.
EMR's P/E Growth Rating (33) in the Electrical Products industry is in the same range as CR (41) in the null industry. This means that EMR’s stock grew similarly to CR’s over the last 12 months.
| CR | EMR | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 62% |
| Momentum ODDS (%) | 2 days ago 69% | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 67% | 2 days ago 61% |
| TrendWeek ODDS (%) | 2 days ago 59% | 2 days ago 59% |
| TrendMonth ODDS (%) | 2 days ago 69% | 2 days ago 56% |
| Advances ODDS (%) | 3 days ago 71% | 9 days ago 62% |
| Declines ODDS (%) | 9 days ago 58% | 2 days ago 56% |
| BollingerBands ODDS (%) | N/A | N/A |
| Aroon ODDS (%) | 2 days ago 70% | 2 days ago 57% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CR’s FA Score shows that 1 FA rating(s) are green while EMR’s FA Score has 3 green FA rating(s).
- CR’s FA Score: 1 green, 4 red.
- EMR’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CR’s TA Score shows that 3 TA indicator(s) are bullish while EMR’s TA Score has 4 bullish TA indicator(s).
- CR’s TA Score: 3 bullish, 4 bearish.
- EMR’s TA Score: 4 bullish, 4 bearish.
Price Growth
CR (@Industrial Machinery) experienced а -1.22% price change this week, while EMR (@Industrial Machinery) price change was -1.86% for the same time period.
The average weekly price growth across all stocks in the @Industrial Machinery industry was -3.76%. For the same industry, the average monthly price growth was -12.92%, and the average quarterly price growth was -18.98%.
Reported Earning Dates
CR is expected to report earnings on Oct 27, 2026.
EMR is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Industrial Machinery (-3.76% weekly)The industry makes and maintains machines for consumers, the industry, and most other companies. While it has traditionally been categorized as heavy industry, some smaller companies are also branching into the light category. The industry is pivotal in providing the equipment for production in businesses like agriculture, mining, industry and construction, gas, electricity and water utilities. It also supplies supporting equipment for almost all sectors of the economy, such as equipment for heating, and air conditioning of buildings. Illinois Tool Works Inc., Parker-Hannifin Corporation and Rockwell Automation Inc are some of the major U.S. companies operating in this industry.
Advertisement
How to use the Cup-and-Handle (Bullish) Pattern in trading
How Did Ticker Tape Evolve from Analog to Digital?
What is the U.S. Dollar (USD) and Why Does It Dominate the Global Economy?
What Is Due Process?
Cisco Systems (CSCO) Q3 2025 Earnings Preview: What to Expect and the Role of Tickeron’s AI Double Agent Trading
CR and
Correlation & Price change
A.I.dvisor indicates that over the last year, CR has been loosely correlated with EMR. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if CR jumps, then EMR could also see price increases.
EMR and
Correlation & Price change
A.I.dvisor indicates that over the last year, EMR has been closely correlated with AME. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if EMR jumps, then AME could also see price increases.